These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33766159)

  • 1. Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders.
    Menon D; Sarpong E; Bril V
    Can J Neurol Sci; 2022 Mar; 49(2):161-167. PubMed ID: 33766159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Personalized Subcutaneous Immunoglobulin Treatment Program for Neurological Patients.
    Suleman A; Theoret L; Bourque P; Pringle E; Cameron DW; Cowan J
    Can J Neurol Sci; 2019 Jan; 46(1):38-43. PubMed ID: 30688201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
    Fu LW; Song C; Isaranuwatchai W; Betschel S
    Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
    Martin A; Lavoie L; Goetghebeur M; Schellenberg R
    Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
    Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
    J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
    Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I
    J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
    Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
    J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
    Haddad É; Barnes D; Kafal A
    Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
    Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
    Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
    [No Abstract]   [Full Text] [Related]  

  • 14. Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.
    Tichy EM; Prosser B; Doyle D
    J Pharm Pract; 2022 Feb; 35(1):106-119. PubMed ID: 32677504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
    Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
    J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.
    Gerth WC; Betschel SD; Zbrozek AS
    Allergy Asthma Clin Immunol; 2014; 10(1):23. PubMed ID: 24872821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
    Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
    J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.